{"ok":true,"entity":{"id":"beam-therapeutics","name":"Beam Therapeutics","entityType":"company","officialName":"Beam Therapeutics Inc.","canonicalName":"Beam Therapeutics","displayName":"Beam Therapeutics","category":"ベースエディティング","shortDescription":"DNA二本鎖を切断せずに1塩基を化学的に書き換えるベースエディティング（塩基編集）を基盤とする米国の遺伝子医薬企業。肝臓を標的とする脂質ナノ粒子送達などを用い、αアンチトリプシン欠乏症などのプログラムを進めている。","primaryCluster":"biotech-genomics","parentEntity":null,"verificationStatus":"draft","website":"https://www.beamtx.com","updatedAt":"2026-08-06T01:18:46.240Z","secondaryClusters":[],"alias":[],"searchKeywords":["ベースエディティング","遺伝子編集"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-06-001","P-05-001"]}